Literature DB >> 28541469

Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia.

Matthew S Simon1, Lars F Westblade2, Alexis Dziedziech1, Joseph E Visone3, Richard R Furman4, Stephen G Jenkins2, Audrey N Schuetz5, Laura A Kirkman1,3.   

Abstract

Babesiosis treatment failures with standard therapy have been reported, but the molecular mechanisms are not well understood. We describe the emergence of atovaquone and azithromycin resistance associated with mutations in the binding regions of the target proteins of both drugs during treatment of an immunosuppressed patient with relapsing babesiosis.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28541469      PMCID： PMC6248624          DOI： 10.1093/cid/cix477

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  15 in total

1.  In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin.

Authors:  Amar Bir Singh Sidhu; Qingan Sun; Louis J Nkrumah; Michael W Dunne; James C Sacchettini; David A Fidock
Journal:  J Biol Chem       Date:  2006-11-15       Impact factor: 5.157

2.  Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance.

Authors:  D C McFadden; S Tomavo; E A Berry; J C Boothroyd
Journal:  Mol Biochem Parasitol       Date:  2000-04-30       Impact factor: 1.759

3.  The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America.

Authors:  Gary P Wormser; Raymond J Dattwyler; Eugene D Shapiro; John J Halperin; Allen C Steere; Mark S Klempner; Peter J Krause; Johan S Bakken; Franc Strle; Gerold Stanek; Linda Bockenstedt; Durland Fish; J Stephen Dumler; Robert B Nadelman
Journal:  Clin Infect Dis       Date:  2006-10-02       Impact factor: 9.079

4.  Ribosomal mutations in Streptococcus pneumoniae clinical isolates.

Authors:  Marja Pihlajamäki; Janne Kataja; Helena Seppälä; John Elliot; Maija Leinonen; Pentti Huovinen; Jari Jalava
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

5.  A global map of genetic diversity in Babesia microti reveals strong population structure and identifies variants associated with clinical relapse.

Authors:  Jacob E Lemieux; Alice D Tran; Lisa Freimark; Stephen F Schaffner; Heidi Goethert; Kristian G Andersen; Suzane Bazner; Amy Li; Graham McGrath; Lynne Sloan; Edouard Vannier; Dan Milner; Bobbi Pritt; Eric Rosenberg; Sam Telford; Jeffrey A Bailey; Pardis C Sabeti
Journal:  Nat Microbiol       Date:  2016-06-13       Impact factor: 17.745

6.  Atovaquone in the treatment of Babesia microti infections in hamsters.

Authors:  M Wittner; J Lederman; H B Tanowitz; G S Rosenbaum; L M Weiss
Journal:  Am J Trop Med Hyg       Date:  1996-08       Impact factor: 2.345

7.  Persistence of babesiosis for >2 years in a patient on rituximab for rheumatoid arthritis.

Authors:  John Raffalli; Gary P Wormser
Journal:  Diagn Microbiol Infect Dis       Date:  2016-02-21       Impact factor: 2.803

8.  Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection.

Authors:  Gary P Wormser; Aakanksha Prasad; Ellen Neuhaus; Samit Joshi; John Nowakowski; John Nelson; Abraham Mittleman; Maria Aguero-Rosenfeld; Jeffrey Topal; Peter J Krause
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

9.  Persistent and relapsing babesiosis in immunocompromised patients.

Authors:  Peter J Krause; Benjamin E Gewurz; David Hill; Francisco M Marty; Edouard Vannier; Ivo M Foppa; Richard R Furman; Ellen Neuhaus; Gail Skowron; Shaili Gupta; Carlo McCalla; Edward L Pesanti; Mary Young; Donald Heiman; Gunther Hsue; Jeffrey A Gelfand; Gary P Wormser; John Dickason; Frank J Bia; Barry Hartman; Sam R Telford; Diane Christianson; Kenneth Dardick; Morton Coleman; Jennifer E Girotto; Andrew Spielman
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

10.  Sequence and annotation of the apicoplast genome of the human pathogen Babesia microti.

Authors:  Aprajita Garg; Anna Stein; William Zhao; Ankit Dwivedi; Roger Frutos; Emmanuel Cornillot; Choukri Ben Mamoun
Journal:  PLoS One       Date:  2014-10-03       Impact factor: 3.240
View more
  17 in total

Review 1.  Babesia microti: from Mice to Ticks to an Increasing Number of Highly Susceptible Humans.

Authors:  Lars F Westblade; Matthew S Simon; Blaine A Mathison; Laura A Kirkman
Journal:  J Clin Microbiol       Date:  2017-07-26       Impact factor: 5.948

2.  Efficacy of the Antimalarial MMV390048 against Babesia Infection Reveals Phosphatidylinositol 4-Kinase as a Druggable Target for Babesiosis.

Authors:  Shengwei Ji; Eloiza May Galon; Mohamed Abdo Rizk; Yunpeng Yi; Iqra Zafar; Hang Li; Zhuowei Ma; Aiko Iguchi; Masahito Asada; Mingming Liu; Xuenan Xuan
Journal:  Antimicrob Agents Chemother       Date:  2022-08-04       Impact factor: 5.938

3.  Efficacy of Short-Term High Dose Pulsed Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-Infections: A Report of Three Cases and Literature Review.

Authors:  Richard I Horowitz; Phyllis R Freeman
Journal:  Antibiotics (Basel)       Date:  2022-07-07

4.  Nested qPCR assay to detect Babesia duncani infection in hamsters and humans.

Authors:  Yanbo Wang; Shangdi Zhang; Jinming Wang; Muhammad Rashid; Xiaorong Wang; Xinyue Liu; Hong Yin; Guiquan Guan
Journal:  Parasitol Res       Date:  2022-10-04       Impact factor: 2.383

Review 5.  Signal peptide peptidase: a potential therapeutic target for parasitic and viral infections.

Authors:  Christopher Schwake; Michael Hyon; Athar H Chishti
Journal:  Expert Opin Ther Targets       Date:  2022-03-07       Impact factor: 6.797

Review 6.  Emerging Tick-Borne Diseases.

Authors:  Susan Madison-Antenucci; Laura D Kramer; Linda L Gebhardt; Elizabeth Kauffman
Journal:  Clin Microbiol Rev       Date:  2020-01-02       Impact factor: 26.132

7.  Activity Comparison of Epigenetic Modulators against the Hemoprotozoan Parasites Babesia divergens and Plasmodium falciparum.

Authors:  Leen N Vanheer; Björn F C Kafsack
Journal:  ACS Infect Dis       Date:  2021-02-18       Impact factor: 5.578

Review 8.  Persistence of Babesia microti Infection in Humans.

Authors:  Evan M Bloch; Sanjai Kumar; Peter J Krause
Journal:  Pathogens       Date:  2019-07-17

9.  Cytochrome b Drug Resistance Mutation Decreases Babesia Fitness in the Tick Stages But Not the Mammalian Erythrocytic Cycle.

Authors:  Joy E Chiu; Isaline Renard; Santosh George; Anasuya C Pal; P Holland Alday; Sukanya Narasimhan; Michael K Riscoe; J Stone Doggett; Choukri Ben Mamoun
Journal:  J Infect Dis       Date:  2022-01-05       Impact factor: 7.759

10.  Validation of Babesia proteasome as a drug target.

Authors:  Marie Jalovecka; David Hartmann; Yukiko Miyamoto; Lars Eckmann; Ondrej Hajdusek; Anthony J O'Donoghue; Daniel Sojka
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2018-08-07       Impact factor: 4.077
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.